Search Results for "Ziagen"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Ziagen. Results 1 to 6 of 6 total matches.
See also: abacavir

Three New Drugs for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 1998  (Issue 1041)
into wide use in clinical trials or "expanded access" programs. They are abacavir (Ziagen − Glaxo Wellcome ...
Combination antiretroviral therapy including protease inhibitors has dramatically changed the treatment of HIV infection and the prognosis of those affected (Medical Letter Handbook of Antimicrobial Therapy, 1998, page 122). Due to limitations and failures with these drugs in many patients, however, three new drugs, none of them protease inhibitors, have rapidly come into wide use in clinical trials or 'expanded access' programs. They are abacavir (Ziagen - Glaxo Wellcome), adefovir (Preveon - Gilead) and efavirenz (Sustiva - DuPont). Efavirenz was recently approved for treatment of...
Med Lett Drugs Ther. 1998 Dec 4;40(1041):114-6 |  Show IntroductionHide Introduction

Two Once-Daily Fixed-Dose NRTI Combinations for HIV

   
The Medical Letter on Drugs and Therapeutics • Feb 28, 2005  (Issue 1203)
) – Ziagen (GSK) 300 mg 300 mg bid or 600 mg once daily $421.80 Lamivudine (3TC) – Epivir (GSK) 150 or 300 ...
The FDA has approved emtricitabine/tenofovir (Truvada - Gilead) and abacavir/lamivudine (Epzicom - GSK), two new fixed-dose combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), for once-daily use in treatment of HIV infection. Two other fixed-dose NRTI combinations were previously approved for twice-daily dosing. Dual NRTI therapy is generally used in either an NNRTI (non-nucleoside reverse transcriptase inhibitor)-based or a PI (protease inhibitor)-based regimen.
Med Lett Drugs Ther. 2005 Feb 28;47(1203):19-20 |  Show IntroductionHide Introduction

Amprenavir: A New HIV Protease Inhibitor

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 1999  (Issue 1057)
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Abacavir (ABC; Ziagen − Glaxo Wellcome)* 300 mg bid 349.20 ...
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
Med Lett Drugs Ther. 1999 Jul 16;41(1057):63-6 |  Show IntroductionHide Introduction

Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2003  (Issue 1169)
(NRTIs) Abacavir (ABC) – Ziagen (GlaxoSmithKline) 300 mg bid $13.44 Didanosine (ddl) – Videx 200 mg bid ...
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Med Lett Drugs Ther. 2003 Nov 10;45(1169):90-2 |  Show IntroductionHide Introduction

Drugs That May Cause Psychiatric Symptoms

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
, 2008 102 Table 2. Some Individual Drugs Drug Reactions Comments Abacavir (Ziagen) Depression ...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.

Click here to view the free full article.
Med Lett Drugs Ther. 2008 Dec 15;50(1301):100-3 |  Show IntroductionHide Introduction

Drugs for HIV Infection

   
Treatment Guidelines from The Medical Letter • Feb 01, 2014  (Issue 138)
) Abacavir [ABC]2 – generic 300 mg tabs 300 mg bid or 2 $459.90 Ziagen (Viiv Healthcare)* 600 mg once/d3 2 ...
Antiretroviral therapy is recommended for all HIV-infected patients, both to reduce the risk of disease progression and to prevent transmission of the virus to others. Various guidelines for treatment of HIV infection are available.
Treat Guidel Med Lett. 2014 Feb;12(138):7-16 |  Show IntroductionHide Introduction